A composition comprising TGFβ, an inflammatory agent and a tryptophan indoleamine-2,3 dioxygenase (IDO) metabolite, in particular, TGFβ, IFNγ and kynurenine, is provided, as well as regulatory mesenchymal stem cell lines or myeloid-derived suppressor cell lines obtained by contacting mesenchymal stem cell lines or myeloid-derived suppressor cell lines, respectively, with the composition. Methods for inhibiting proliferation of T cells, reducing Th17 and Tc17 differentiation of activated T cells and inflammation or for treating inter alia graft-versus-host disease (GVHD), comprising administering the cell lines, are further provided.

The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and; or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.

Provided are blocking agents to IL-1α, IL-1β, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1α, IL-1β or both in their circulation.

The object of the present invention is novel release systems comprising specific hyaluronic acid amides combined with therapeutically and/or biologically active proteins with a mainly hydrophobic nature, for sustained, slow release over time which increases the efficacy of the medicament and the patient's compliance.

Provided herein are methods and compositions for enhancement of stem-cell based immunomodulation and promotion of tissue repair.

Provided herein are methods and compositions for enhancement of stem-cell based immunomodulation and promotion of tissue repair.

Methods for treating a subject for arthritis are provided. Aspects of the methods include administration to the subject a rs419598/rs315952/rs9005-haplotype-informed therapeutic regimen. In some instances, the methods include administering to the subject a therapeutic regimen that antagonizes interleukin-1 (IL-1) activity and/or a disease modifying osteoarthritis drug (DMOAD) if the subject has been identified as having a TTG rs419598/rs315952/rs9005 haplotype. Also provided are compositions for use in practicing the methods.

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.

Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.